1. The Bavarian Cell Therapy Catalyst
  2. Projects

Projects

The Consortium BAYCELLator comprises eight scientific projects, with four focusing on higher-level enabler technologies: viral vectors and systems (Project 1), universal donor cells (Projects 2 and 6), and process automation (Project 3). These projects are designed to yield benefits not only for the BAYCELLator projects in later development phases but also for future projects within Bavaria. The aim is to expedite the development and testing of future approaches by leveraging the knowledge gained from these endeavors.

Furthermore, all projects within the consortium are dedicated to addressing significant medical challenges, striving to pioneer innovative treatments for refractory cancer patients. In this context, Projects 1, 2, 6, and 7 focus on various hematological conditions, while Projects 3, 4, 5, and 8 center on solid tumor diseases.

Project 1

Development of a chimeric antigen receptor that specifically and selectively recognizes acute myeloid leukemia (AML) blasts

Project 2

Arming IPSC-derived NK cells with a CAR for treatment of AML                                                        

Project 3

Intelligent process automation (IPA)

Project 4

Development of NK cells as an alternative cell source for adoptive cell therapy

Project 5

Augmentation of anti-tumor efficacy of integrin αvβ3-specific CAR T cells

Project 6

Development of anti-CD28 chimeric antigen receptor (CAR) T cells

Project 7

Generation of hypoimmunogenic TCR or CAR cells from iPSCs

Project 8

Optimization of HBV-specific T cells for hepatocellular carcinoma therapy